Literature DB >> 1450174

LDL particle size distribution. Results from the Framingham Offspring Study.

H Campos1, E Blijlevens, J R McNamara, J M Ordovas, B M Posner, P W Wilson, W P Castelli, E J Schaefer.   

Abstract

Using 2-16% gradient gel electrophoresis, we examined low density lipoprotein (LDL) particle size in relation to plasma lipoproteins in 1,168 women and 1,172 men from the Framingham Offspring Study. In addition, we studied the effect of dietary intake on LDL size in a subset of the population. Seven LDL size peaks were identified, with the largest, LDL 1, being found in the density range 1.019-1.033 g/ml; LDL 2 and LDL 3 in d = 1.033-1.038 g/ml; LDL 4 and LDL5 in d = 1.038-1.050 g/ml; and the smallest, LDL 6 and 7, in d = 1.050-1.063 g/ml. Seventy-seven percent of the population had one major and at least one minor LDL peak. Secondary LDL peaks accounted for 23% of the total LDL relative area, based on laser scanning densitometry. LDL size distribution was skewed toward larger LDL particles in women (prevalence of LDL 1, 30% and of LDL 2, 31%), whereas men exhibited a more symmetric distribution (prevalence of LDL 3, 42%). The prevalence of small (< 255 A), dense (d > 1.038 g/ml) LDL particles 4-7 was 33% in men, 5% in premenopausal women, and 14% in postmenopausal women. In agreement with previous reports, small, dense LDL particles were significantly (p < 0.0001) associated with increased triglyceride and apolipoprotein (apo) B levels and decreased HDL cholesterol and apo A-I levels. In addition, we found a significant (p < 0.0001) association between LDL cholesterol and LDL size. The highest LDL cholesterol levels were found among women with LDL 4 (148 mg/dl) and men with LDL 3-5 (138 mg/dl). In addition, the presence of LDL 3 or 4 as secondary peaks was significantly associated with higher LDL cholesterol levels, while smaller secondary LDL peaks were associated with higher triglyceride levels. We also found that compared with subjects with optimal LDL cholesterol levels (< 130 mg/dl), individuals with high-risk LDL cholesterol levels (> or = 160 mg/dl) had 1) a higher prevalence of LDL 3 and 4 (women only) and a lower prevalence of LDL 1 and 2 (women only) and 2) 11% higher LDL cholesterol to apo B ratios, even when matched for LDL particle size. Furthermore, low saturated fat and cholesterol intakes were significantly associated (p < 0.01) with smaller LDL particles. Therefore, the identification of small, dense LDL particles per se may not be a good indicator of coronary artery disease risk in population studies.(ABSTRACT TRUNCATED AT 400 WORDS)

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1450174     DOI: 10.1161/01.atv.12.12.1410

Source DB:  PubMed          Journal:  Arterioscler Thromb        ISSN: 1049-8834


  35 in total

1.  Effects of atorvastatin 10 mg and fenofibrate 200 mg on the low-density lipoprotein profile in dyslipidemic patients: A 12-week, multicenter, randomized, open-label, parallel-group study.

Authors:  Jean-Claude Ansquer; Christophe Corda; Karine Le Malicot; Valerie Jessent
Journal:  Curr Ther Res Clin Exp       Date:  2009-04

2.  Complementary Cholesterol-Lowering Response of a Phytosterol/α-Lipoic Acid Combination in Obese Zucker Rats.

Authors:  Todd C Rideout; Bradley Carrier; Shin Wen; Amy Raslawsky; Richard W Browne; Scott V Harding
Journal:  J Diet Suppl       Date:  2015-02-09

3.  Multilocus genetic determinants of LDL particle size in coronary artery disease families.

Authors:  J I Rotter; X Bu; R M Cantor; C H Warden; J Brown; R J Gray; P J Blanche; R M Krauss; A J Lusis
Journal:  Am J Hum Genet       Date:  1996-03       Impact factor: 11.025

4.  Inherited susceptibility determines the distribution of dense low-density lipoprotein subfraction profiles in familial combined hyperlipidemia.

Authors:  S J Bredie; L A Kiemeney; A F de Haan; P N Demacker; A F Stalenhoef
Journal:  Am J Hum Genet       Date:  1996-04       Impact factor: 11.025

5.  High-Density Lipoprotein Proteomic Composition, and not Efflux Capacity, Reflects Differential Modulation of Reverse Cholesterol Transport by Saturated and Monounsaturated Fat Diets.

Authors:  Marcella O'Reilly; Eugene Dillon; Weili Guo; Orla Finucane; Aoibheann McMorrow; Aoife Murphy; Claire Lyons; Daniel Jones; Miriam Ryan; Michael Gibney; Eileen Gibney; Lorraine Brennan; Margarita de la Llera Moya; Muredach P Reilly; Helen M Roche; Fiona C McGillicuddy
Journal:  Circulation       Date:  2016-04-14       Impact factor: 29.690

6.  Regulation of low-density lipoprotein particle size distribution in NIDDM and coronary disease: importance of serum triglycerides.

Authors:  S Lahdenperä; M Syvänne; J Kahri; M R Taskinen
Journal:  Diabetologia       Date:  1996-04       Impact factor: 10.122

7.  Sex differences in the associations of visceral adiposity, homeostatic model assessment of insulin resistance, and body mass index with lipoprotein subclass analysis in obese adolescents.

Authors:  Jacquelyn A Hatch-Stein; Andrea Kelly; Samuel S Gidding; Babette S Zemel; Sheela N Magge
Journal:  J Clin Lipidol       Date:  2016-02-16       Impact factor: 4.766

8.  Significance of small dense low-density lipoprotein as a risk factor for coronary artery disease and acute coronary syndrome.

Authors:  Sung Woo Kwon; Se-Jung Yoon; Tae Soo Kang; Hyuck Moon Kwon; Jeong-Ho Kim; Jihyuk Rhee; Sung-Ju Lee; Jong-Kwan Park; Jae Yun Lim; Young Won Yoon; Bum Kee Hong
Journal:  Yonsei Med J       Date:  2006-06-30       Impact factor: 2.759

9.  Reversal of small, dense LDL subclass phenotype by normalization of adiposity.

Authors:  Patty W Siri-Tarino; Paul T Williams; Harriet S Fernstrom; Robin S Rawlings; Ronald M Krauss
Journal:  Obesity (Silver Spring)       Date:  2009-06-04       Impact factor: 5.002

10.  Effects of Armolipid Plus on small dense LDL particles in a sample of patients affected by familial combined hyperlipidemia.

Authors:  Marco Gentile; Ilenia Calcaterra; Alfonso Strazzullo; Carmen Pagano; Delia Pacioni; Enza Speranza; Paolo Rubba; Gennaro Marotta
Journal:  Clin Lipidol       Date:  2015-11-23
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.